FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DOTSON JERROLD DUANE 		2. Issuer Name and Ticker or Trading Symbol

VistaGen Therapeutics, Inc. [ VTGN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
VP, CFO AND SECRETARY
(Last)          (First)          (Middle)

C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/29/2018
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $10   8/29/2018     D         678   (1)   10/30/2012   10/30/2022   Common Stock   678   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      678       8/29/2018   10/30/2022   Common Stock   678   $0   678   D  
 
Stock Option (Right to Buy)   $10   8/29/2018     D         4323   (1)   10/30/2014   10/30/2022   Common Stock   4323   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      4323       8/29/2018   10/30/2022   Common Stock   4323   $0   4323   D  
 
Stock Option (Right to Buy)   $8   8/29/2018     D         1000   (2)   10/27/2015   10/27/2023   Common Stock   1000   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      1000       8/29/2018   10/27/2023   Common Stock   1000   $0   1000   D  
 
Stock Option (Right to Buy)   $3.49   8/29/2018     D         75000   (3)     (4) 6/19/2026   Common Stock   75000   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      75000         (4) 6/19/2026   Common Stock   75000   $0   75000   D  
 
Stock Option (Right to Buy)   $3.80   8/29/2018     D         50000   (5)     (6) 11/9/2026   Common Stock   50000   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      50000         (6) 11/9/2026   Common Stock   50000   $0   50000   D  
 
Stock Option (Right to Buy)   $1.96   8/29/2018     D         100000   (7)     (8) 4/26/2027   Common Stock   100000   $0   0   D  
 
Stock Option (Right to Buy)   $1.50   8/29/2018     A      100000         (8) 4/26/2027   Common Stock   100000   $0   100000   D  
 

Explanation of Responses:
(1)  The reporting person agreed to cancellation of an option granted to him on 10/30/2012 in exchange for a new option having a lower exercise price.
(2)  The reporting person agreed to cancellation of an option granted to him on 10/27/2013 in exchange for a new option having a lower exercise price.
(3)  The reporting person agreed to cancellation of an option granted to him on 6/19/2016 in exchange for a new option having a lower exercise price.
(4)  The option vests periodically over a period of four years commencing 6/19/2016.
(5)  The reporting person agreed to cancellation of an option granted to him on 11/9/2016 in exchange for a new option having a lower exercise price.
(6)  The option vests monthly over a period of three years commencing 11/9/2016.
(7)  The reporting person agreed to cancellation of an option granted to him on 4/26/2017 in exchange for a new option having a lower exercise price.
(8)  The option vests monthly over a period of three years commencing 4/26/2017.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DOTSON JERROLD DUANE
C/O VISTAGEN THERAPEUTICS, INC.
343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080

VP, CFO AND SECRETARY

Signatures
/s/ Jerrold D. Dotson 8/31/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more VistaGen Therapeutics Charts.
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more VistaGen Therapeutics Charts.